We aim to develop best-in-class, small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders that can reach more patients in need by decreasing the treatment burden on patients and healthcare providers.
Our lead pipeline program, LSR-1019, is a novel formulation of 5-MeO-DMT, a potent, fast-acting, and rapidly clearing serotonergic psychedelic for patients with treatment-resistant depression and other debilitating neuropsychiatric disorders. Orally administered 5-MeO-DMT is pharmacologically inactive due to rapid metabolism by enzymes in the gut and liver. LSR-1019 is a proprietary sublingual tablet formulation of 5-MeO-DMT that dissolves under the tongue within seconds and is absorbed without the need for water. This approach is scalable, eliminates the need for burdensome drug delivery systems, simplifies administration, and offers the potential for more consistent exposure and more predictable therapeutic benefit in patients. We hold an exclusive worldwide license for Catalent’s Zydis® fast-dissolving tablet technology for our 5-MeO-DMT program.
Treatment-resistant depression occurs when patients with major depressive disorder do not respond adequately to two lines of therapy. There is a tremendous need for new therapies for patients not adequately controlled with currently available treatments. Serotonergic neuroplastogens have been shown to induce favorable structural and functional neural plasticity, resulting in rapid and dramatic improvement in patients with treatment-resistant depression. Existing clinical data suggest that 5-MeO-DMT has the potential to offer best-in-class efficacy in people with treatment-resistant depression.
We are also advancing additional programs focused on migraine and cluster headache and additional neuropsychiatric and neurological disorders.
Undisclosed neuropsychiatric indication #2 & indication #3
Prophylactic treatments for migraine and cluster headache
Next generation neuroplastogens for additional neuropsychiatric and neurological disorders
LSR-1019, our lead program, is a proprietary sublingual formulation of 5-MeO-DMT. LSR-1019 is a best-in-class psychedelic therapeutic in development for treatment-resistant depression and additional neuropsychiatric indications. We hold an exclusive worldwide license for Catalent’s Zydis® fast-dissolving tablet technology for our 5-MeO-DMT program.
LSR-2000 is a late-stage discovery program evaluating serotonergic neuroplastogens for the prevention of migraines and cluster headaches. Emerging data has shown that traditional psychedelics such as LSD and psilocybin may offer benefit to patients for migraine and cluster headache prophylaxis. We believe our program has the potential for a new generation of prophylactic headache therapeutics that will leverage serotonergic biology in a novel, optimized product profile.
LSR-3000 is a discovery program focused on developing therapies suitable for chronic dosing by maintaining broad serotonergic receptor activation without hallucinogenic effects or by preserving activity at the 5HT2a and other serotonin receptor subtypes while eliminating activity at the 5HT2b receptor.